Ocean Chiropractic Center
- Shockwave Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
- Migraine Treatment
San Francisco, CA
Migraine care in San Francisco blends headache medicine anchored around UCSF, CPMC, Kaiser San Francisco, and Dignity Health St Mary's with integrative clinics offering IV magnesium, nerve blocks, and peptide protocols. Demand reflects a tech-industry and biohacking-fluent patient base.
Evidence-based care uses triptans, gepants, lasmiditan, and anti-CGRP monoclonals for acute and preventive treatment, plus onabotulinumtoxinA for chronic migraine and FDA-cleared neuromodulation devices. Regenerative and integrative adjuncts in San Francisco, California include IV magnesium, occipital and sphenopalatine ganglion blocks, ketamine infusions for refractory cases, and HBOT (investigational for cluster headache). California Medical Board strict rules on NP scope and medical spa oversight shapes prescribing and compounding authority.
With migraine clinics on Regenerated.com in San Francisco, patients can compare whether a clinic offers a proper headache workup, follows ICHD-3 criteria, and clearly distinguishes FDA-approved from off-label options.
Regulatory context
Repetitive transcranial magnetic stimulation (rTMS) is regulated as a Class II prescription device. The first 510(k) clearance went to NeuroStar in 2008 for treatment-resistant major depressive disorder. Subsequent clearances expanded the on-label scope to obsessive-compulsive disorder (BrainsWay deep TMS, 2018), smoking cessation (BrainsWay, 2020), anxious depression as an adjunct indication (2021), and migraine via single-pulse TMS devices such as eNeura SpringTMS and SAVI Dual. Biofeedback instruments are cleared under 21 CFR 882.1425 as Class II devices for relaxation training and stress reduction. EEG-based neurofeedback systems hold 510(k) clearances in the same category. Cranial electrotherapy stimulation, tDCS wellness devices, and many vagus nerve stimulation accessories sold direct to consumers are not cleared as medical devices, and clinical claims beyond cleared indications are off-label.
The Medical Board of California investigates TMS clinics for off-label marketing, corporate practice of medicine violations, and improper supervision of technicians. California has a strong corporate practice of medicine doctrine, meaning non-physician-owned entities cannot employ physicians or control clinical decisions at TMS or neurofeedback clinics. The attorney general and district attorneys have pursued actions against neurofeedback providers advertising unproven cures for autism, ADHD, and traumatic brain injury. California insurers require documented failed antidepressant trials before covering TMS for major depression.